Aging is associated with metabolic diseases such as type 2 diabetes mellitus, cardiovascular disease, cancer, and neurodegeneration. Aging contributes to common processes including metabolic dysfunction, DNA damage, and reactive oxygen species generation. Although glycolysis has been linked to cell growth and proliferation, the mechanisms by which the activation of glycolysis by aging regulates fibrogenesis in the lung remain unclear. The objective of this study was to determine if glucose transporter 1 (GLUT1)-induced glycolysis regulates age-dependent fibrogenesis of the lung. Mouse and human lung tissues were analyzed for GLUT1 and glycolytic markers using immunoblotting. Glycolytic function was measured using a Seahorse apparatus. To study the effect of GLUT1, genetic inhibition of GLUT1 was performed by short hairpin RNA transduction, and phloretin was used for pharmacologic inhibition of GLUT1. GLUT1-dependent glycolysis is activated in aged lung. Genetic and pharmacologic inhibition of GLUT1 suppressed the protein expression of a-smooth muscle actin, a key cytoskeletal component of activated fibroblasts, in mouse primary lung fibroblast cells. Moreover, we demonstrated that the activation of AMPactivated protein kinase, which is regulated by GLUT1-dependent glycolysis, represents a critical metabolic pathway for fibroblast activation. Furthermore, we demonstrated that phloretin, a potent inhibitor of GLUT1, significantly inhibited bleomycin-induced lung fibrosis in vivo. These results suggest that GLUT1-dependent glycolysis regulates fibrogenesis in aged lung and that inhibition of GLUT1 provides a potential target of therapy of age-related lung fibrosis.
Fibrotic interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF), are more prevalent in aging populations (1, 2) . IPF is a rapidly progressive, fatal lung disease with a median survival of ,3 years after diagnosis (3) . Fibrosis is characterized by the accumulation of extracellular matrix (ECM) proteins, activated myofibroblasts, and inflammatory cells (4) . We and other groups have reported recently that aged mice, compared with their younger counterparts, have greater lung injury and fibrosis (5, 6) . Glycolytic reprogramming has been shown to play an important role in the pathogenesis of lung fibrosis (7) . Recent studies have reported that patients with IPF exhibit higher glycolytic activity in fibrotic areas, with positive retention index values being a strong predictor of deterioration in pulmonary function and of higher mortality (8, 9) .
Glycolysis is a critical pathway in glucose metabolism that provides intermediates for energy generation (10) (11) (12) . Cellular metabolic pathways, including glycolysis and fatty acid synthesis, have been shown to play an important role in lung injury (13, 14) . Glucose transporter 1 (GLUT1), a member of the facilitative GLUT transporter family (SLC2), is the most highly conserved and widely distributed glucose transporter in mammalian cells (15, 16) . Changes in metabolic state and oxidative stress can regulate GLUT1 expression (17) . Previous work has shown several signaling molecules, such as cAMP, p53, phosphoinositide 3-kinase, and Akt, can regulate GLUT1 expression and function (18) (19) (20) . Despite these findings, the regulation of fibrogenesis by the metabolic changes in aging cells has not been well elucidated.
The AMP-activated protein kinase (AMPK) is a central energy sensor that exists as a heterotrimer composed of a catalytic a subunit with regulatory b and g subunits (21) (22) (23) . When cellular energy supply is low, AMPK obtains the kinase activity by phosphorylation of the a subunit at Thr172 (24) . The sensitivity of AMPK activation declines with aging, and the increasing responsiveness of AMPK activation plays a crucial role in extending lifespan in some species (25) (26) (27) (28) . Recently, it has been suggested that reagents that enhance AMPK activation reduce organ fibrosis (29) .
In the current study, we demonstrate that GLUT1-dependent glycolysis regulates the activation of fibrogenesis in aged lung in vivo and in vitro. GLUT1-dependent glycolysis was activated in lung tissues of aged mice relative to young mice. Genetic and pharmacologic inhibition of GLUT1 suppressed the protein expression of a-smooth muscle actin (a-SMA), which is a cytoskeletal component of contractile actin stress fibers, in mouse primary fibroblasts. The activation of AMPK, which is a key metabolic regulator, by GLUT1 inhibition significantly reduced the protein expression of a-SMA in mouse primary fibroblasts. Pharmacologic inhibition of GLUT1 by phloretin, a potent GLUT1 inhibitor, suppressed bleomycin-induced lung fibrosis in vivo. Taken together, our results suggest that the activation of GLUT1-dependent glycolysis by aging is critical for fibrogenesis in the lung.
Materials and Methods

Reagents
Bleomycin and phloretin were obtained from Cayman Chemical (Ann Arbor, MI). Recombinant mouse transforming growth factor-b (TGF-b) 1 was obtained from R&D Systems (Minneapolis, MN). MG132, 2-deoxyglucose (2DG), 5-aminoimidazole-4-carboxamide 1-b-D-ribofuranoside (AICAR), and dorsomorphin were obtained from Sigma-Aldrich (St. Louis, MO).
Animal Studies
Male C57BL/6 mice of 2 months and 18 months of age were purchased from the National Institute on Aging Mouse Colony. Mice were exposed to phosphate-buffered saline or bleomycin (0.01 mg/mouse) via oropharyngeal aspiration. Phloretin (10 mg/kg) was started on the day of bleomycin administration or on Day 7 after bleomycin and was given by intraperitoneal injection every other day for 14 days. All animal experimental protocols were approved by the institutional animal care and use committee at Weill Cornell Medicine.
Isolation and Culture of Murine Lung Fibroblasts
Primary lung fibroblasts were isolated and cultured as described previously (30) .
Transduction of GLUT1 Short Hairpin RNA For stable knockdown of mouse glut1, two independent short hairpin RNAs (shRNAs) (TRCN00000305719 and TRCN00000311413, Sigma-Aldrich) were used. Aged mouse lung fibroblasts (2 3 10 5 cells/well) were seeded in 6-well plates and were transduced with shRNA lentiviral constructs against mouse GLUT1 or nontarget shRNA (SHC016, SigmaAldrich) controls.
Immunoblot Analysis
Immunoblotting was performed as described previously (5) . Anti-b-actin (4,967), -a-tubulin (2,144), -AMPKa (5,831), -phospho-AMPKa (2,535), -Smad3 (9,513), -phospho-Smad3 (9,520) antibodies and a glycolytic sampler kit (8, 337) were obtained from Cell Signaling (Danvers, MA). Anti-GLUT1 (ab40084), -collagen type 1 (ab21286) antibodies were from Abcam (Cambridge, MA). Antifibronectin (sc-6952) was from Santa Cruz Biotechnology (Dallas, TX). Anti-a-SMA (A2547) was from Sigma-Aldrich.
Quantitative Reverse Transcriptase-Polymerase Chain Reaction
Total RNA was isolated from cultured cells and tissues using the TRIzol reagent (Thermo Fischer Scientific, Waltham, MA), per manufacturer's instructions. Quantitative reverse transcriptasepolymerase chain reaction was performed as described in our previous study (5) .
Assessment of Fibrosis
Lung tissues were formalin fixed and hematoxylin and eosin stained by the Research Pathology Laboratory at Weill Cornell Medical College. Fibrosis was evaluated histologically using Masson trichrome stains and biochemically using the Sircol collagen assay kit (S1000; Biocolor, County Antrim, UK) or hydroxyproline assay (MAK008; Sigma-Aldrich) according to the manufacturer's instructions.
Immunohistochemistry
Paraffin-embedded murine lung tissue sections went through antigen retrieval using target retrieval buffer (Dako; Carpinteria, CA). Anti-GLUT1 (ab40084, Abcam) antibody and biotinylated goat antimouse antibody (Vector Laboratories Inc., ON, Canada) were used. Slides were developed using Vector NovoRed (Vector Laboratories Inc., Burlington, ON, Canada), and were counterstained with Gill's hematoxylin (Sigma-Aldrich).
Glycolytic Function Assay
Primary murine cells were plated on XF96 cell culture microplates (101085-004,
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Seahorse Bioscience, North Billerica, MA). The extracellular acidification rate (ECAR) or oxygen consumption rate (OCR) as parameters of glycolytic flux were measured on a Seahorse XF96 bioanalyzer, using the XF Glycolysis Stress Test kit according to the manufacturer's instructions (102194-100, Seahorse Bioscience) (see online supplement for a detailed experimental protocol).
Statistical Analysis
Error bars represent the SEM, as indicated in figure legends. All statistical tests were analyzed by Student's two-tailed t test for comparison of two groups and by analysis of variance (with post hoc comparisons using Dunnett's test) for comparison of multiple groups using GraphPad Prism v. 6.0 (La Jolla, CA). P , 0.05 was considered statistically significant.
Results
GLUT1-Dependent Glycolysis Is Activated in Aged Lung
To investigate the metabolic changes in aged lung, we first analyzed the glycolytic function of single-cell lung cell suspensions isolated from young (2-month-old) and aged (18-month-old) murine lung using the GentleMacs tissue dissociation apparatus. We assessed the ECAR as a measure of lactate production (a surrogate for the glycolytic rate) and the mitochondrial OCR. The rate of glycolysis is the ECAR after the addition of glucose. Oligomycin (2 mM) was injected after glucose (10 mM) to inhibit mitochondrial respiration. 2DG (100 mM) injection reduced ECAR down to baseline by inhibiting hexokinase. Importantly, aged cells had high ECAR when compared with young cells (Figure 1A ), whereas the OCR was comparable ( Figure 1B ). Of note, although oligomycin generally shifts energy production to glycolysis to increase ECAR in transformed cells, there was decreased ECAR after oligomycin injection in both primary young and aged cells. These results suggest that the glycolytic phenotype is elevated in aged lung relative to young lung.
To demonstrate the target of high glycolytic phenotype in aged lung, we analyzed the expression of enzymes in glycolytic pathway in lung tissues. Glucose transporters are responsible for modulating the uptake and use of glucose. Importantly, the protein expression of GLUT1 in lung tissues from aged mice was significantly increased compared with that from young mice ( Figures 1C and 1D ), whereas the Glut1 gene expression was unchanged ( Figure 1E ). We next investigated whether defective function of the ubiquitin proteasome system, a major degradation pathway of intracellular proteins, could contribute to altered posttranslational regulation of GLUT1. In response to MG132, a well-characterized proteasome inhibitor, protein levels of GLUT1 in aged lung fibroblasts were further increased ( Figure 1F ). These results suggest that GLUT1 induction is regulated by mechanisms involving proteasomal degradation. We next examined whether other glycolytic enzymes were responsible for the augmented glycolysis in the aged cells. Interestingly, the protein expressions of other glycolytic enzymes were comparable between aged and young lung tissues (see Figure E1A in the online supplement). Altogether, these results suggest that the induction of GLUT1 protein expression is responsible for the high glycolytic phenotype in aged lung.
Age-Dependent Lung Fibrogenesis Is Associated with the Expression of GLUT1
We evaluated the fibroproliferative activity of aged lung cells in response to bleomycininduced lung injury. Fibrotic changes and collagen deposition in lung tissues after bleomycin instillation were measured using Masson trichrome staining. There was a detectable accumulation of collagen in the subepithelial area and interalveolar septum forming fibrotic foci at 14 days postinstillation ( Figure 2A ). To validate these results, we measured the acid-soluble collagen levels in lung tissues by Sircol assay. Consistently, the level of acid-soluble collagen was elevated significantly after bleomycin treatment in aged lung when compared with young lung (Figures 2B and E2A). Similarly, protein expression of collagen and fibronectin was also higher in aged lung tissue lysates ( Figures 2C-2E ). Moreover, aged mice showed progressive loss of body weight after bleomycin instillation, whereas young mice maintained their body weight ( Figure E2B ). To examine whether fibrotic changes in response to bleomycin-induced lung injury are linked to GLUT1 expression, we next examined GLUT1 protein levels in young and aged lung tissue after bleomycin instillation, using immunoblot and immunohistochemical analysis. Protein expression of GLUT1 was increased significantly in the aged lung, not only at baseline but also with bleomycin treatment ( Figures 2F, 2G , and E2C). More specifically, GLUT1 expression was increased in various structural cells, including fibroblast foci, epithelial cells, subepithelial cells, and inflammatory cells, in aged lung tissues when compared with young lung tissues ( Figure 2H) . Importantly, protein expression of GLUT1 was markedly increased in fibrotic areas with high collagen deposits ( Figures 2H  and 2I ). Taken together, these results suggest that age-driven lung fibrogenesis is associated with increased expression of GLUT1.
Glycolysis Is a Critical Metabolic Pathway for the Activation of Aged Fibroblasts
To investigate the effect of biological aging on glycolysis in fibroblasts, we measured the ECAR in primary young and aged lung fibroblasts. Consistent with high GLUT1 protein expression, the ECAR was significantly increased in aged fibroblasts ( Figures 3A and S3) . Figures 3B  and 3C ). Furthermore, an increase in glucose concentration augmented a-SMA expression in primary aged fibroblasts (Figures 3D and 3E ). Taken together, these results suggest that glycolysis is a critical pathway for the activation of lung fibroblasts in response to TGF-b.
GLUT1-Dependent Glycolysis is Critical for the Activation of Aged Fibroblasts
To analyze whether enhanced GLUT1 expression plays a critical role in the activation of aged lung fibroblasts, we next investigated the impact of GLUT1 deficiency on responses to TGF-b stimulation. To this end, primary aged lung fibroblasts were transfected with two independent GLUT1-specific shRNA before stimulation. ECAR induction in response to TGF-b was suppressed significantly in aged fibroblasts transduced with GLUT1 shRNA when compared with control ( Figure 4A) . Consistently, protein expression of a-SMA in response to TGF-b was also decreased by GLUT1 shRNA relative to control shRNA ( Figures 4B,  E4A , and E4B).
We next investigated the impact of pharmacologic inhibition of GLUT1 in aged fibroblast responses to TGF-b stimulation. We inhibited the activity of GLUT1 in aged fibroblasts via treatment with phloretin, a competitive GLUT1 inhibitor. As with GLUT1 shRNA, phloretin suppressed the induction of ECAR by TGF-b ( Figure 4C) . Moreover, the protein expression of a-SMA in response to TGF-b was decreased in a time-and dosedependent manner when compared with vehicle control (Figures 4D, 4E , E4C, and E4D). These results suggest that GLUT1-dependent glycolysis is critical for the activation of aged lung fibroblasts in response to TGF-b.
GLUT1-Dependent Glycolysis Inhibits the Activation of AMPK in Aged Fibroblasts
Next, we sought to investigate whether AMPK activation can serve as a downstream mechanism for GLUT1-dependent glycolysis. The phosphorylation of AMPK was suppressed significantly in the aged fibroblasts in response to TGF-b (Figures 5A and E5A) . To determine the effect of GLUT1 on the activation of AMPK in aged lung fibroblasts, we used two independent shRNA for GLUT1. AMPK phosphorylation was enhanced by GLUT1 knockdown when compared with vehicle control (Figures 5B and E5B ). We next investigated the impact of pharmacologic inhibition of GLUT1 in AMPK activation. Phloretin induced AMPK phosphorylation in a dose-and timedependent manner ( Figures 5C, 5D , E5C, and E5D). We also examined the role of glycolysis in AMPK activation by 2DG treatment to inhibit glycolysis. Similar to the effect of phloretin, 2DG increased AMPK phosphorylation ( Figures 5E, 5F , E5E, and E5F). However, it had no effect on TGF-binduced Smad3 phosphorylation ( Figures E6A and E6B) . These results suggest that GLUT1-dependent glycolysis regulates the activation of AMPK.
Phosphorylation of AMPK Attenuates the Activation of Aged Lung Fibroblasts
Because GLUT1-dependent glycolysis regulates AMPK activation, we examined whether the activation of AMPK can suppress lung fibroblast activation. We activated the AMPK signaling pathway using AICAR, an activator of AMPK. Consistent with previous observation, the phosphorylation of AMPK was enhanced in AICAR-stimulated lung fibroblasts in a dose-and timedependent manner ( Figures 6A, 6B , E7A, and E7B). Importantly, the protein expression of a-SMA in response to TGF-b was attenuated by AICAR treatment compared with vehicle control (Figures 6C and E7C) . Next, we examined the effect of AMPK activation by using dorsomorphin, a potent AMPK inhibitor. Treatment with dorsomorphin significantly decreased AMPK phosphorylation in young fibroblasts ( Figures 6D, 6E, E7D , and E7E). Unlike the case of AICAR treatment, the protein expression of a-SMA in response to TGF-b was enhanced by dorsomorphin treatment in young fibroblasts ( Figures 6F and E7F ). These results suggest that AMPK activation is a critical metabolic pathway involved in fibroblast activation in response to TGF-b.
Pharmacologic Inhibition of GLUT1 Suppressed Lung Fibrogenensis in Aged Mice after Bleomycin Challenge
To investigate whether pharmacologic inhibition of GLUT1 can suppress lung fibrogenesis in vivo, we examined the impact of phloretin treatment on bleomycin-induced lung fibrosis. When compared with control, phloretin treatment inhibited the accumulation of collagen in the subepithelial area and interalveolar septum forming fibrotic foci ( Figure 7A ). The induction of acidsoluble collagen by bleomycin treatment was also decreased significantly by phloretin treatment when compared with vehicle control ( Figure 7B ). Moreover, phloretin treatment decreased the protein levels of collagen and fibronectin in aged lung tissues in response to bleomycin when compared with vehicle control (Figures 7C-7E) . Furthermore, phloretin improved morbidity in bleomycin-instilled aged mice, whereas inflammatory responses were comparable between phloretin-treated and control mice ( Figures E8A and E8B ). These results suggest that pharmacologic inhibition of GLUT1-dependent glycolysis in aged lung results in decreased fibrogenesis in response to bleomycin instillation.
Discussion
Fibrotic interstitial lung diseases, including IPF, are more prevalent in aging populations, with a sharp increase in incidence in those older than 50 years. To date, there is evidence that patients with IPF exhibit higher glycolytic activity in fibrotic areas; however, the mechanisms that contribute to this phenotype have not been well explored.
In this report, we demonstrate that GLUT1-dependent glycolysis provides a critical mechanism for age-driven lung fibrogenesis. We also demonstrate that GLUT1-dependent glycolysis is a crucial metabolic pathway that is required for the activation and differentiation of lung fibroblasts. Furthermore, we show that pharmacologic inhibition of GLUT1 decreases collagen accumulation and lung fibrogenesis in response to bleomycin instillation. Fibroblasts are the most common cell type of the connective tissues and are the principal source of the extensive ECM in the lung. Our current study illustrates that increased GLUT1 expression in primary aged fibroblasts contributes to elevated glycolytic rates and lactate production, which may increase glucose-dependent metabolic pathways within these cells. Furthermore, pharmacologic inhibition of GLUT1 resulted in decreased lung fibrogenesis in aged lung in response to bleomycin instillation. Enhanced GLUT1 expression in aged fibroblasts may serve as an age-associated mechanism to increase glucose availability while limiting oxidative metabolism of excess pyruvate and fatty acids when excess energetic requirements are placed on a cell. An age-associated increase in GLUT1-mediated glucose metabolism may contribute to alterations in metabolic programming and increased fibrotic accumulation of ECM in response to prolonged tissue injury and chronic inflammation.
Overexpression of GLUT1 has been observed in many human cancers, and GLUT1 expression levels have been inversely correlated with prognosis (32, 33) . The function of GLUT1 in the context of aging and the molecular mechanisms leading to constitutive up-regulation of aerobic glycolysis in the aged cell have not been well defined. Here we demonstrate that GLUT1 expression and glycolysis are increased significantly in both untreated and bleomycin-instilled aged lung. These findings support the notion that aging is a steady adaptation process to cellular senescence and mitochondrial dysfunction. Augmenting glucose influx instead of increasing glycolytic enzymes in aged cells may serve as a mechanism to avert oncogenic transformation, which could occur via the indiscriminate, global upregulation of glycolytic enzymes. However, it is possible that elevated GLUT1-mediated glucose uptake and metabolism may propel aged fibroblasts into a hyperinflammatory state, with increased activation of proinflammatory mediators. Previous work has illustrated a mechanistic link between GLUT1 overexpression and PAI-1, a known nuclear factor-kB target gene (34) . It is plausible that age-associated enhancements in GLUT1 expression in fibroblasts may contribute to increased inflammation and fibrotic lesion development in aged lung in response to bleomycin instillation. Regulation of glucose transporters in aged cells may prove to be an important and unique metabolic phenomenon that can be targeted in developing treatments for age-related diseases.
In this study, we demonstrated that GLUT1 expression in aged lung was significantly increased without substantial changes in the levels of its mRNA. The question then arises as to how the protein expression of GLUT1 is upregulated in aged lung. The answer could be provided by previous publications that show that GLUT1 expression, at least in part, is regulated by a protein degradation pathway (35, 36) . Alterations in protein turnover during biological aging have been correlated with decreased activity of the proteasome system and autophagy (37) , which may account for the increase in GLUT1 expression in the aged lung. In line with previous reports, our preliminary data demonstrate that enhanced GLUT1 expression in aged lung is regulated, at least in part, by proteasomal degradation. We can speculate that significantly decreased proteasome expression and activity in aged lung tissues contribute to heightened GLUT1-mediated glycolysis and fibrogenesis, when compared with young controls. Nonetheless, determining the specific mechanism responsible for GLUT1 degradation will require further study. AMPK is a key metabolic regulator in several intracellular metabolic pathways including the use of glucose, fatty acids oxidation, and fatty acid synthesis (21, 22) . The activation of AMPK is a critical event for homeostasis of cellular energy levels by regulating anabolic or catabolic energy pathways (21, 22) . Although AMPK has been linked to aging and lifespan (38) , little is known about the role of AMPK in aged lung. Interestingly, our results showed the down-regulation of AMPK activation in aged lung compared with young lung. These results suggest that aging mediates the metabolic alteration in the lung via changes in various cellular pathways that control AMPK.
Glycolysis in media was determined by ECAR, which is predominantly from the excretion of lactic acid per unit time after its conversion from pyruvate. ECAR measurements reflect a change in the pH of the assay medium. It is important to note that additional metabolic processes in cells, such as CO 2 production by the trichloroacetic acid cycle, may alter pH and thereby confound ECAR measurements. To increase the accuracy of our measurements, we examined the impact of inhibitor treatment on ECAR responses in aged fibroblasts. Specifically, in response to GLUT1 inhibition by phloretin, glucose transport 4 inhibition (data not shown), or knockdown by shRNA, there is a significant reduction in ECAR when compared with vehicle-treated aged fibroblasts (Figure 4 ). Taken together, our results illustrate that although additional metabolic processes may contribute to ECAR, glycolysis-mediated lactate production underlies the significant differences between young and aged fibroblasts. Future work will need to be performed to examine the impact of aging on additional metabolic processes and the contribution of these responses to residual ECAR detection in fibroblasts.
Age-associated metabolic dysfunction is linked to risk factors for a variety of diseases such as type 2-diabetes, cardiovascular disease, and stroke (39, 40) .
The respiratory function of the lung has also been shown to decrease with biological aging (41) . Our unpublished data show that the expression of genes in mechanistic target of rapamycin and fatty acid synthesis were decreased significantly in aged lung tissues. It is possible that as the supply of oxygen and respiratory function is deceased in aged lung (42) , the aerobic metabolic functions, including oxidative phosphorylation in mitochondria or fatty acid metabolism, are also similarly suppressed (42) (43) (44) (45) .
Conclusions
In conclusion, inhibition of lung fibrogenesis by pharmacologic inhibition of GLUT1-dependent glycolysis provides a potential target of therapy for age-driven fibrotic disease. These findings may have broad implications for therapeutic targeting in human diseases, not only those of the lung, but also those in other fibrosis-susceptible organ systems. n
